NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Search Results for VaxInnate


Filter Articles: Clinical News | Consumer News | Business News | All News | More Options

Results 1 - 20      Next >


Refine Search
Display Mode: Context | Summary
3M Licenses Vaccine Adjuvants to VaxInnate
2009 NOV 26 ... 3M Drug Delivery Systems has signed an agreement with VaxInnate Corporation under which VaxInnate acquires the use of ...
Subject: 3M
Price: $3.00
*
Experts Available to Discuss: US Responding as If Swine Flu Will Be Pandemic
2009 MAY 11 ... several highly qualified experts to comment on this story: VACCINES Dr. Alan Shaw , VaxInnate Corporation: Alan Shaw, PhD is President and CEO of...
Subject: ExpertSource
Price: $3.00
*
Microneedle Devices for Therapeutics and Diagnostics Edging Toward Commercialization
2009 AUG 17 ... level of commercial activity is heating up. 3M Drug Delivery Systems has an agreement in VaxInnate that will allow the vaccine developer to use 3M's Microstructured Transdermal System to ...
Subject: Drug Delivery
Price: $3.00
*
VaxInnate Corporation Closes $30 Million Round of Financing; Wellcome Trust Leads Round
2009 MAY 18 ... VaxInnate Corporation, a biotechnology company pioneering breakthrough technology that could ...
Subject: VaxInnate Corporation
Price: $3.00
*
VaxInnate Welcomes David J. Williams to its Board of Directors
2009 MAR 2 ... VaxInnate Corporation announced that David J. Williams, retired chairman and chief executive ...
Subject: VaxInnate Corporation
Price: $3.00
*
VaxInnates Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study
2009 MAY 11 ... on Vaccine Research. The new data support the potential of VAX125, VaxInnate's investigational hemagglutinin (HA)-flagellin flu vaccine, to rapidly meet global ...
Subject: Immunization
Price: $3.00
*
Xcellerex Appoints David J. Williams, Retired Chairman/CEO of Sanofi Pasteur, to its Board of Directors
2009 APR 13 ... the Hospital Service Association of Northeastern Pennsylvania, AllOne Health Group, and VaxInnate Corporation. Internationally respected, Williams served as the first ...
Subject: Xcellerex, Inc.
Price: $3.00
*
3M and VaxInnate Collaborate to Develop Flu Vaccine Patch
2008 NOV 3 ... 3M Drug Delivery Systems has entered into an agreement with VaxInnate Corporation to develop a flu vaccine patch for use against a pandemic flu outbreak. The ...
Subject: 3M
Price: $3.00
*
Research results from J.W. Huleatt and co-authors update knowledge of influenza vaccines
2008 MAR 17 ... Additional information can be obtained by contacting J.W. Huleatt, VaxInnate Corporation, 300 George Street, New Haven, CT 06511 USA.. The publisher ...
Subject: Influenza Vaccines
Price: $3.00
*
UTMB researchers test new vaccine to fight multiple vaccine strains
2008 SEP 1 ... for Vaccine Development at UTMB and the study's principal investigator, said that VaxInnate's M2e universal vaccine could possibly protect against seasonal and pandemic influenza ...
Subject: University of Texas Medical Branch at Galveston
Price: $3.00
*
Vaxinnate to Present Positive Results from Clinical Trial of Universal Flu Vaccine Candidate at ICAAC/IDSA Meeting
2008 OCT 27 ... VaxInnate Corporation, a biotechnology company pioneering breakthrough technology to develop novel ...
Subject: Immunization
Price: $3.00
*
VaxInnate's M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
2008 SEP 1 ... VaxInnate Corporation announced that its M2e universal influenza vaccine candidate was safe and ...
Subject: VaxInnate Corporation
Price: $3.00
*
VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
2008 OCT 13 ... VaxInnate Corporation, a biotechnology company pioneering breakthrough technology to develop novel ...
Subject: VaxInnate Corporation
Price: $3.00
*
VaxInnates M2e Universal Influenza Vaccine Candidate Demonstrates Safety and Immunogenicity in Phase I Clinical Study
2008 SEP 8 ... VaxInnate Corporation announced that its M2e universal influenza vaccine candidate was safe and ...
Subject: Flu Vaccines
Price: $3.00
*
VaxInnates Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
2008 OCT 20 ... VaxInnate Corporation, a biotechnology company pioneering breakthrough technology to develop novel ...
Subject: Flu Vaccines
Price: $3.00
*
VaxInnates Universal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Clinical Study
2008 NOV 10 ... IDSA annual meetings here today. This first clinical study of VaxInnate's M2e universal flu vaccine candidate also validates the Cranbury, NJ-based ...
Subject: Immunization
Price: $3.00
*

Results 1 - 20      Next >




-----------------------
PR Login